The Lancet

[177 Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, ope…

Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival.